MENS Jyong Biotech: Enterprise Value-to-Revenue Multiple

Official company branding of jyongbio.com (MENS)

Jyong Biotech Ltd (MENS) produces plant-based pharmaceuticals in China and Taiwan, leveraging patents in the men's health sector. The company's EV/Sales multiple, with GURU.Markets data illustrated on this chart, confirms the current valuation, while the 0.00 level indicates the parameter's status. However, a cash deficit and rising debt driven by R&D expenditures coexist with a strong USP in urology that meets FDA standards.

MENS: Jyong Biotech Corp EV/Sales Multiple 11/23/2025 - 11/20/2026

Jyong Biotech Corp - analytical breakdowns and key metrics (MENS)

- price and consensus price forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Fundamental company valuation:MENS (jyongbio.com)
Product sample of Jyong Biotech Limited

The scale of operations at Jyong Biotech Ltd (MENS) is driven by the speed of AI-powered drug synthesis, yet the EV/Revenue multiple allows for an assessment of the business's actual market value by neutralizing the impact of leverage. By analyzing this chart, an investor can determine the premium paid for future growth, recognizing that prolonged clinical trials create a time lag between expenditures and actual cash inflows.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|LGND (Ligand Pharmaceuticals Incorporated) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amneal Pharmaceuticals Inc AMRX|EV/Sales Multiple PRGO|Enterprise Value-to-Revenue Coefficient ALVO|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio